DUBLIN – Shares in GW Pharmaceuticals plc surged more than 130 percent in London on Monday on news that Epidiolex (cannabidiol) met the primary endpoint of a pivotal phase III trial in Dravet syndrome, a rare and severe form of treatment-resistant epilepsy that emerges in infancy.